NexImmune, Inc.

NASDAQ:NEXI

0.2 (USD) • At close December 26, 2024
Bedrijfsnaam NexImmune, Inc.
Symbool NEXI
Munteenheid USD
Prijs 0.205
Beurswaarde 285,907
Dividendpercentage 0%
52-weken bereik 0.15 - 28.695
Industrie Biotechnology
Sector Healthcare
CEO Ms. Kristi Jones R.Ph.
Website https://www.neximmune.com

An error occurred while fetching data.

Over NexImmune, Inc.

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy,

Vergelijkbare Aandelen

Aquestive Therapeutics, Inc. logo

Aquestive Therapeutics, Inc.

AQST

3.52 USD

Eledon Pharmaceuticals, Inc. logo

Eledon Pharmaceuticals, Inc.

ELDN

4.35 USD

Acasti Pharma Inc. logo

Acasti Pharma Inc.

ACST

3.37 USD

Eargo, Inc. logo

Eargo, Inc.

EAR

2.57 USD

Astria Therapeutics, Inc. logo

Astria Therapeutics, Inc.

ATXS

9.15 USD

Zynerba Pharmaceuticals, Inc. logo

Zynerba Pharmaceuticals, Inc.

ZYNE

1.3 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)